Education
About Us
Working with TipRanks
Follow Us
Innate Pharma SA (FR:IPH)
:IPH
Earnings Data
Report Date
Mar 19, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.31Last Year’s EPS
-0.31Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call reflected a strategic shift towards prioritizing high-value clinical assets with promising progress in key trials. However, there were concerns over reduced R&D spending and the deprioritization of certain research areas, alongside the departure of a key scientific leader. The company's financial position remains stable, providing support for its strategic objectives.Company Guidance
Strategic Focus on High-Value Clinical Assets
Innate Pharma has decided to focus its investment on three high-value clinical assets: IPH4502, lacutamab, and monalizumab, which are expected to create meaningful value for patients and shareholders.
IPH4502 Phase I Enrollment Progress
Enrollment in the first-in-human Phase I study of IPH4502 is progressing well, with completion expected by the end of Q1 2026. Preliminary safety and activity data are anticipated in the first half of 2026.
Lacutamab's Potential in CTCL
Lacutamab has received FDA breakthrough therapy designation for relapsed or refractory Sézary syndrome, with strong long-term follow-up data presented at ASCO 2025, supporting its potential for accelerated approval.
Monalizumab Phase III Trial Progress
The Phase III PACIFIC-9 trial for monalizumab, conducted by AstraZeneca, is fully recruited with primary completion expected in the first half of 2026 and data expected in the second half of 2026.
Financial Stability
Innate Pharma reported EUR 70.4 million in cash and financial assets as of June 30, 2025, providing a cash runway until the end of Q3 2026.
FR:IPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
FR:IPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Sep 17, 2025 | €1.79 | €1.76 | -1.78% |
Mar 27, 2025 | €1.86 | €1.88 | +0.91% |
Sep 12, 2024 | €2.18 | €2.12 | -2.75% |
Mar 21, 2024 | €2.19 | €2.17 | -0.69% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Innate Pharma SA (FR:IPH) report earnings?
Innate Pharma SA (FR:IPH) is schdueled to report earning on Mar 19, 2026, Before Open (Confirmed).
What is Innate Pharma SA (FR:IPH) earnings time?
Innate Pharma SA (FR:IPH) earnings time is at Mar 19, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Innate Pharma SA stock?
The P/E ratio of Innate Pharma SA is N/A.
What is FR:IPH EPS forecast?
FR:IPH EPS forecast for the fiscal quarter 2025 (Q4) is -0.31.